Concord Medical - Public Comps and Valuation Multiples

Concord Medical Overview

About Concord Medical

Concord Healthcare Group Co Ltd is a healthcare service provider in China that specializes in oncology. The company caters to both cancer patients and third-party medical institutions. It operates its own medical institutions to provide comprehensive oncology healthcare services to cancer patients using its medical professionals and advanced precision radiation therapy. It also provides medical equipment, software, and related services to third-party medical institutions. The company's revenue is generated from its hospital business and its medical equipment, software, and related services segment. Substantially all of the company's revenue is generated from the PRC.

Founded

2008

HQ

Employees

567

Website

concordmedical.com

Sectors

Hospitals & Clinics

Financials

Last FY Revenue $49.6M

Last FY EBITDA -$30.2M

EV

$1.0B

Valuation Multiples

Multiples.vc

Valuation Multiples for 12K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Concord Medical Financials

In the most recent fiscal year, Concord Medical achieved revenue of $49.6M and an EBITDA of -$30.2M.

Concord Medical expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Concord Medical valuation multiples based on analyst estimates

Concord Medical P&L

	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	XXX	$49.6M	XXX	XXX	XXX
Gross Profit	XXX	-$8.6M	XXX	XXX	XXX
Gross Margin	XXX	-17%	XXX	XXX	XXX
EBITDA	XXX	-$30.2M	XXX	XXX	XXX
EBITDA Margin	XXX	-61%	XXX	XXX	XXX
EBIT	XXX	-$50.7M	XXX	XXX	XXX
EBIT Margin	XXX	-102%	XXX	XXX	XXX
Net Profit	XXX	-$56.6M	XXX	XXX	XXX
Net Margin	XXX	-114%	XXX	XXX	XXX
Net Debt	XXX	$369M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

Concord Medical Stock Performance

As of May 30, 2025, Concord Medical's stock price is HKD 7 (or $1).

Concord Medical has current market cap of HKD 4.9B (or $625M), and EV of HKD 8.0B (or $1.0B).

See Concord Medical trading valuation data

Concord Medical Stock Data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$1.0B	$625M	XXX	XXX	XXX	XXX	n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Concord Medical Valuation Multiples

As of May 30, 2025, Concord Medical has market cap of $625M and EV of $1.0B.

Concord Medical's trades at 20.7x EV/Revenue multiple, and -33.9x EV/EBITDA.

Equity research analysts estimate Concord Medical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Concord Medical's P/E ratio is not available.

See valuation multiples for Concord Medical and 12K+ public comps

Concord Medical Financial Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$625M	XXX	$625M	XXX	XXX	XXX
EV (current)	$1.0B	XXX	$1.0B	XXX	XXX	XXX
EV/Revenue	n/a	XXX	20.7x	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	-33.9x	XXX	XXX	XXX
EV/EBIT	n/a	XXX	-20.2x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	n/a	XXX	-11.1x	XXX	XXX	XXX
EV/FCF	n/a	XXX	-15.7x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Concord Medical Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Concord Medical Margins & Growth Rates

Concord Medical's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.

Concord Medical's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Concord Medical's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Concord Medical and other 12K+ public comps

Concord Medical Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	-61%	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	13%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	8%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	85%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial